Background. Tumor budding is a promising prognostic indicator in several cancers especially in colorectal cancer. However, only few studies have been conducted to assess and validate its prognostic value in laryngeal squamous cell carcinoma; none of which used pancytokeratin immunohistochemistry. In view of the modest results of treatment of laryngeal squamous cell carcinoma, the need of new prognostic indicators becomes of paramount importance. Aim of the Study. We aim to evaluate tumor budding in laryngeal squamous cell carcinoma, by haematoxylin and eosin, as well as by pancytokeratin immunohistochemistry. Material and Methods. A retrospective study on 118 cases of laryngeal squamous cell carcinoma from archives of Pathology Lab of Ain Shams University Specialized Hospital and Ain Shams University Hospitals from January 2014 to January 2017. The ENT and histopathology reports were reviewed to determine clinicopathologic data of the patients. Results. Tumor budding shows high statistically significant relations ( for each) with important clinicopathological parameters of laryngeal carcinoma (site, grade, tumor stage, lymph node stage, lymph node extracapsular invasion, and vascular invasion). The extent of tumor budding correlated with overall survival, local recurrence disease free, and distant metastasis disease free ( for each). Multivariate analysis showed tumor budding to be an independent prognostic factor affecting progression-free survival. There was a moderate agreement between H&E and IHC by pancytokeratin as regards detection of budding among study cases (). Conclusions. Tumor budding was correlated with poor prognostic clinicopathologic indicators in laryngeal squamous cell carcinoma. It is recommended to use pancytokeratin immunohistochemistry to evaluate tumor budding in laryngeal squamous cell carcinoma especially in confusing cases.

中文翻译：

---

通过常规和免疫组织化学染色评估喉癌中肿瘤出芽的潜在预后价值

背景。肿瘤出芽是几种癌症特别是结直肠癌的有前途的预后指标。然而，只有少数研究评估和验证了其在喉鳞状细胞癌中的预后价值。其中没有一个使用泛细胞角蛋白免疫组织化学。鉴于喉鳞状细胞癌的治疗效果不佳，需要新的预后指标变得至关重要。研究目的。我们的目标是通过苏木精和伊红以及泛细胞角蛋白免疫组织化学评估喉鳞状细胞癌中的肿瘤出芽。材料与方法. 回顾性研究2014年1月至2017年1月艾因夏姆斯大学专科医院病理实验室和艾因夏姆斯大学附属医院档案中118例喉鳞状细胞癌病例。回顾耳鼻喉科和组织病理学报告，确定患者的临床病理资料。结果。肿瘤出芽显示出高度统计学显着的关系（每个）都有喉癌的重要临床病理参数（部位、分级、肿瘤分期、淋巴结分期、淋巴结包膜外侵犯和血管侵犯）。肿瘤出芽的程度与总生存率、无局部复发疾病和无远处转移疾病相关。每个）。多变量分析显示肿瘤出芽是影响无进展生存期的独立预后因素。在研究病例中检测出芽方面，H&E 和泛细胞角蛋白 IHC 之间存在中等一致性（）。 结论。肿瘤出芽与喉鳞状细胞癌预后不良的临床病理学指标相关。建议使用泛细胞角蛋白免疫组织化学来评估喉鳞状细胞癌中的肿瘤出芽，尤其是在混淆病例中。